Skip to main content

Maria Cristina Centeno Mediavilla

Institutions of which they are part

Senior researcher
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Maria Cristina Centeno Mediavilla

Institutions of which they are part

Senior researcher
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Projects

Targeting Myeloid-Derived Suppressor Cells to prevent HIV/STI acquisition

IP: Meritxell Genesca Ferrer
Collaborators: Maria Cristina Centeno Mediavilla, Nuria Laia Rodriguez Mias, Bibiana Planas Ribas, Yannick Hoyos Mallecot, Josep Castellví Vives, Laura Mañalich Barrachina, María José Buzón Gómez, Maider Arando Lasagabaster
Funding agency: Fundació La Marató de TV3
Funding: 199685
Reference: 20181410
Duration: 10/05/2019 - 31/12/2022

Caracterización de los reservorios VIH latentes del tejido cervical y nuevas estrategias para eliminarlos

IP: Meritxell Genesca Ferrer
Collaborators: Vicenç Falcó Ferrer, Maria Cristina Centeno Mediavilla
Funding agency: Instituto de Salud Carlos III
Funding: 111320
Reference: PI17/01470
Duration: 01/01/2018 - 31/12/2021

Desarrollo de una herramienta de diagnóstico precoz de cáncer de endometrio en biopsia líquida cervical

IP: Eva Colas Ortega
Collaborators: Vicente Bebia Conesa, Maria Cristina Centeno Mediavilla, Desarrollo de una herramienta de diagnóstico precoz de cáncer de endometrio en biopsia líquida cervical, Silvia Cabrera Diaz
Funding agency: Instituto de Salud Carlos III
Funding: 93170
Reference: PI17/02155
Duration: 01/01/2018 - 30/06/2022

STELLA trial: Ensayo clínico randomizado comparando la via de abordaje de la linfadenectomía aórtica laparoscópica: via transperitoneal vs extraperitoneal en cáncer de endometrio y ovario

IP: -
Collaborators: Maria Cristina Centeno Mediavilla, Fco Javier De la Torre Fdez de Vega, STELLA trial: Ensayo clínico randomizado comparando la via de abordaje de la linfadenectomía aórtica laparoscópica: via transpe, Montserrat Cubo Abert
Funding agency: Instituto de Salud Carlos III
Funding: 36905
Reference: PI14/01817
Duration: 01/01/2015 - 30/06/2019

Related news

The ten groups within the Cancer Area combine basic, translational and clinical research to identify new targets, biomarkers and therapeutic strategies

The study evaluated the results of combining SYD985, a HER2 antibody conjugated to a potent cytotoxic drug, and niraparib, an inhibitor of DNA damage repair.

Researchers from the centre took part in international debates on AI in healthcare, spin-offs emerging from research were presented, and several initiatives linked to VHIR received recognition in the field of entrepreneurship.

Related professionals

Carlos Hobeich Naya

Carlos Hobeich Naya

Research technician
Transfusional Medicine
Read more
Aroa  Gomez  Brey

Aroa Gomez Brey

Research technician
Donation and transplantation of organs, tissues and cells
Read more
Albert Moreno Mingorance

Albert Moreno Mingorance

Postdoctoral researcher
Microbiology
Read more
Raquel Ibarz Lopez

Raquel Ibarz Lopez

Administration and Management
Psychiatry, Mental Health and Addictions
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.